Rival antirheumatics Simponi and Cimzia receive EU positive opinions
This article was originally published in Scrip
Executive Summary
Two competing anti-TNF therapies, Centocor (Johnson & Johnson) and Schering-Plough's Simponi (golimumab) and UCB's Cimzia (certolizumab pegol), have received positive endorsements for approval from the EU's CHMP.